Moderna's Authorized COVID-19 Booster Increases Omicron Neutralizing Antibody Levels 37-Fold

Moderna Inc MRNA has reported preliminary neutralizing antibody data against the omicron variant following its COVID-19 vaccine booster candidates at 50 µg and 100 µg dose levels. 

• The currently authorized 50 µg booster of mRNA-1273 increased neutralizing antibody levels against omicron approximately 37-fold compared to pre-boost levels.
• The 100 µg dose of mRNA-1273 increased neutralizing antibody levels approximately 83-fold compared to pre-boost levels.
• Related Link: Moderna CEO Says Omicron Variant To Likely Hit COVID-19 Vaccines Effectiveness: FT
• The multivalent candidates boosted omicron-specific neutralizing antibody levels similar at the 50 µg and 100 µg levels. 
• The Company also reported that a 100 µg booster dose of mRNA-1273 was generally safe and well-tolerated. 
• Adverse reactions following the 100 µg booster dose were higher than the authorized 50 µg booster dose of mRNA-1273.
• Moderna says that given the strength of mRNA-1273 and the speed at which the omicron variant is spreading, its first line of defense against omicron will be a booster dose of mRNA-1273.
• The Company will also continue to develop an omicron-specific variant vaccine (mRNA-1273.529) that it expects to advance into clinical trials in early 2022.
• Also See: Pfizer Plans To Evaluate Third Shot For Its COVID-19 Vaccine In Kids Below 5 Years.
• Price Action: MRNA shares 8.18% at $318.90 during the premarket session on the last check Monday.
• Photo by Spencer Davis from Pixabay